Allogeneic hematopoietic stem cell transplantation for mature T/NK-cell lymphomas in children.
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
27 Jan 2024
27 Jan 2024
Historique:
received:
03
11
2023
revised:
21
01
2024
accepted:
22
01
2024
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
29
1
2024
Statut:
aheadofprint
Résumé
Mature T/NK-cell lymphomas (MTCLs) are a heterogeneous group of lymphoproliferative disorders, relatively rare in adults and children. Allogeneic hematopoietic stem cell transplantation (HSCT) can be considered in some cases as a consolidation and is the first choice for refractory forms and relapses. We retrospectively analyzed 19 pediatric patients with MTCL who received allogeneic hematopoietic stem cell transplantation from a haploidentical or unrelated donor on the αβ T cell depletion platform. Among the studied patients, cutaneous T-cell lymphoma was diagnosed in five, hepatosplenic γδT-cell lymphoma in four, ALK-positive anaplastic large cell lymphoma in nine patients, and one had nasal T/NK cell lymphoma. All patients received myeloablative conditioning based on treosulfan or total body irradiation (TBI). Non-relapse mortality was 5%, the cumulative incidence of relapse or progression at five years was 27%, five-year event-free survival was 67%, and 5-year overall survival was 78%. Thus, our data support that allogeneic αβ T-cell-depleted HSCT can provide long-term overall survival of children with high-risk mature T-cell lymphomas.
Identifiants
pubmed: 38286354
pii: S2666-6367(24)00173-8
doi: 10.1016/j.jtct.2024.01.077
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.